title: Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits.
abstract: Over the past years, the importance of the renin-angiotensin-aldosterone system in atrial fibrillation (AF) pathophysiology has been recognised. Lately, the role of aldosterone in AF pathophysiology and mineralocorticoid receptor (MR) antagonism in "upstream" AF treatment is discussed. Hypothesising that selective MR antagonism might also influence atrial ion currents (L-type calcium current [I (Ca,L)], transient outward potassium current [I (to)], sustained outward potassium current [I (sus)]) and their tachycardia-induced remodelling, the effects of an eplerenone treatment were studied in a rabbit model. Six groups each with four animals were built. Animals of the control group received atrial pacing leads, but in contrast to the pacing groups, no atrial tachypacing (600 per minute for 24 and 120 h immediately before heart removal) was applied. Animals of the eplerenone groups were instrumented/paced as the corresponding control/pacing groups, but were additionally treated with eplerenone (7 days before heart removal). Atrial tachypacing was associated with a reduction of I (Ca,L). I (to) was decreased after 24 h of tachypacing, but returned to control values after 120 h. In the absence of rapid atrial pacing, MR antagonism reduced I (Ca,L) to a similar extent as 120 h of tachypacing alone. Based on this lower "take-off level", I (Ca,L) was not further decreased by high-rate pacing. I (to) and its expected tachycardia-induced alterations were not influenced by MR antagonism. In our experiments, selective MR antagonism influenced atrial I (Ca,L) and its tachycardia-induced alterations. As changes of I (Ca,L) are closely linked with atrial calcium signalling, the relevance of these alterations in AF pathophysiology and, accordingly, AF treatment is likely and has to be further evaluated.
authors.affiliation: Kardiologie und Kreislauferkrankungen, Eberhard Karls Universität Tuebingen, Otfried-Mueller-Straße 10, 72076, Tuebingen, Germany. roman.laszlo@gmx.de
authors.forename: Roman
authors.initials: R
authors.lastname: Laszlo
authors.forename: Kerstin
authors.initials: K
authors.lastname: Bentz
authors.forename: Agnes
authors.initials: A
authors.lastname: Konior
authors.forename: Christian
authors.initials: C
authors.lastname: Eick
authors.forename: Birgit
authors.initials: B
authors.lastname: Schreiner
authors.forename: Klaus
authors.initials: K
authors.lastname: Kettering
authors.forename: Juergen
authors.initials: J
authors.lastname: Schreieck
mesh_terms: D000818:Animals; D001281:Atrial Fibrillation / Q000378:metabolism* / Q000503:physiopathology; D020746:Calcium Channels, L-Type / Q000378:metabolism; D002304:Cardiac Pacing, Artificial; D004195:Disease Models, Animal; D004553:Electric Conductivity; D000077545:Eplerenone; D005260:Female; D006325:Heart Atria / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D006329:Heart Conduction System / Q000187:drug effects / Q000378:metabolism; D015640:Ion Channel Gating / Q000187:drug effects; D000451:Mineralocorticoid Receptor Antagonists; D015221:Potassium Channels / Q000378:metabolism; D011817:Rabbits; D013148:Spironolactone / Q000031:analogs & derivatives / Q000494:pharmacology; D013610:Tachycardia / Q000378:metabolism* / Q000503:physiopathology
chemical_list: D020746:Calcium Channels, L-Type; D000451:Mineralocorticoid Receptor Antagonists; D015221:Potassium Channels; D013148:Spironolactone; D000077545:Eplerenone
references.citation: Heart Rhythm. 2007 Apr;4(4):499-507
references.pmid: 17399641
references.citation: Circulation. 2004 Sep 21;110(12):1520-6
references.pmid: 15381657
references.citation: Hypertension. 2002 Aug;40(2):124-9
references.pmid: 12154101
references.citation: Cardiovasc Res. 2005 Aug 1;67(2):216-24
references.pmid: 15919070
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2006 Dec;374(3):153-62
references.pmid: 17075718
references.citation: Heart Rhythm. 2008 Jun;5(6 Suppl):S1-6
references.pmid: 18456193
references.citation: Dtsch Med Wochenschr. 2006 Apr 13;131(15):817-20
references.pmid: 16607602
references.citation: Circulation. 2000 Mar 14;101(10):1179-84
references.pmid: 10715266
references.citation: Int J Cardiol. 2002 Jul;84(1):33-9; discussion 39-40
references.pmid: 12104061
references.citation: Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2257-66
references.pmid: 16428353
references.citation: Curr Opin Pharmacol. 2007 Apr;7(2):219-24
references.pmid: 17276728
references.citation: Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):44-52
references.pmid: 18084345
references.citation: Br J Pharmacol. 2010 Apr;159(8):1581-3
references.pmid: 20388187
references.citation: J Physiol. 2001 Nov 15;537(Pt 1):151-60
references.pmid: 11711569
references.citation: Circulation. 2005 Jun 14;111(23):3025-33
references.pmid: 15939817
references.citation: Circ Res. 2002 May 17;90(9):939-50
references.pmid: 12016259
references.citation: Physiol Rev. 1994 Apr;74(2):365-507
references.pmid: 8171118
references.citation: Circ Res. 2009 Oct 23;105(9):876-85
references.pmid: 19762679
references.citation: Circ Arrhythm Electrophysiol. 2008 Apr;1(1):62-73
references.pmid: 19808395
references.citation: Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1378-84
references.pmid: 12842811
references.citation: Int J Clin Pract. 2009 Jul;63(7):982-5
references.pmid: 19570114
references.citation: Gen Physiol Biophys. 2008 Sep;27(3):174-8
references.pmid: 18981532
references.citation: Am J Physiol. 1998 Jul;275(1):H301-21
references.pmid: 9688927
references.citation: Physiol Rev. 2000 Jan;80(1):173-210
references.pmid: 10617768
references.citation: Circ J. 2006 May;70(5):610-4
references.pmid: 16636499
references.citation: Cardiovasc Res. 1999 Oct;44(1):121-31
references.pmid: 10615396
references.citation: J Am Coll Cardiol. 2003 Mar 5;41(5):858-69
references.pmid: 12628735
references.citation: J Physiol. 2005 Nov 15;569(Pt 1):153-62
references.pmid: 16166161
references.citation: Circ Res. 1999 Dec 3-17;85(12):1139-45
references.pmid: 10590240
references.citation: Physiol Rev. 2007 Apr;87(2):425-56
references.pmid: 17429037
references.citation: Exp Physiol. 2009 Jun;94(6):675-83
references.pmid: 19395659
references.citation: Cardiovasc Res. 2002 May;54(2):230-46
references.pmid: 12062329
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2010 Mar;381(3):195-206
references.pmid: 19784635
references.citation: Circulation. 1995 Oct 1;92(7):1954-68
references.pmid: 7671380